Skip to main content
SpringerLink
Log in

Prolactinomas and Pregnancy

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Prolactinomas are the most frequent pituitary tumors. Treatment of infertility in such tumors usually is very successful. On the other hand, reports of pituitary tumor growth during pregnancy have been described since bromocriptine started to be used. Since then, dopamine agonists (DA) have been increasingly used as the first-choice treatment of prolactinomas, with surgery being reserved for resistance or persistent intolerance to DA or for special situations. More recently other DA, such as quinagolide and cabergoline have shown better tolerance than bromocriptine with similar or greater efficacy. Cabergoline is now the first choice drug but its use in pregnancy is still under evaluation. We followed 71 term pregnancies in women bearing microprolactinomas. Of the 22 patients with previous surgery, none presented symptoms of tumor growth. Of the 41 pregnant patients treated with bromocriptine alone, only one (2.4%) presented with headaches, which regressed with drug reintroduction. Fifty one term pregnancies in patients with macroprolactinomas were followed by us. Of those, 21 were in patients with previous surgery and none of them presented clinical evidence of tumor growth. On the other hand, of the 30 patients treated only with pre-gestational bromocriptine, 11 (37%) manifested complaints related to tumor growth. A non-hormonal contraceptive should be the use along with a DA drug until tumor shrinkage within sellar boundaries has been evidenced. After pregnancy has been confirmed, the DA can be withdrawn and the patient must be closely followed. If tumor expansion is suspected, confirmation can be made through MRI and by visual field testing. Reintroduction of bromocriptine in such cases can lead to tumor reduction and clinical improvement. Surgery can also be employed as treatment for symptomatic tumor growth in pregnancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Burrow GN, Wortzman G, Rewcastle HB, Holgate RC, Kovacs K. Microadenomas of the pituitary and abnormal sellar tomograms in an unselected autopsy. N Engl J Med 1981;304:156.

    Article  CAS  PubMed  Google Scholar 

  2. Hardy J. Transsphenoidal surgery of hypersecreting pituitary tumors. In: Kohler PO and Ross GT (eds.), Diagnosis and treatment of Pituitary Tumors, Amsterdam: Excerpta Medica, 1973, p. 179.

    Google Scholar 

  3. Miyai K, Ichihara K, Kondo K, Mori S. Asymptomatic hyperprolactinaemia and prolactinoma in the general population-mass screening by paired assays of serum prolactin. Clin Endocrinol (Oxf) 1986;25:549–554.

    CAS  Google Scholar 

  4. Hardy J. Transsphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg 1969;16:185–217.

    CAS  PubMed  Google Scholar 

  5. Marino RJr, Bronstein MD. The role of pituitary surgery in the treatment of prolactinomas. In: Meireles RMR, Machado A, Póvoa LC (eds.), Clinical Endocrinology : Proceedings of the 18th Brazilian Congress of Endocrinology and Metabolism, Rio de Janeiro, Junho, 1988, pp. 12–17. Amsterdam-New York-Oxford Excepta Medica. 1988, pp. 53–56.

  6. Molitch ME. Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 1999;28:143–169.

    Article  CAS  PubMed  Google Scholar 

  7. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinemic patients previously unsuccessfully treated with dipaminergic drugs. Isr J Med Sci 1991;27:375–379.

    CAS  PubMed  Google Scholar 

  8. Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf 1996;14:228–238.

    CAS  PubMed  Google Scholar 

  9. Musolino NRC, Cunha Neto MB, Bronstein MD. Cabergoline as an alternative for medical treatment of prolactinomas: Experience in bromocriptine intolerance/resistance. Arq Bras Endocrinol Metab 2000;44:139–143.

    Article  Google Scholar 

  10. Colao A, Di Sarno A, Sarnacchiaro F, Ferone D, Di Renzo G, Merola B, Annunziato L, Lombardi G. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 1997;82:876–883.

    CAS  PubMed  Google Scholar 

  11. Duranteau L, Chanson P, Lavoinne A, Horlait S, Lubetzki J, Kuhn JM. Effect of the new dopaminergic agonist CV 205–502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas. Clin Endocrinol (Oxf) 1991;34:25–29.

    CAS  Google Scholar 

  12. Verhelst J, Abs R, Maiter D, van der Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A. Cabergoline in the treatment of hyperprolactinemia: A study in 455 patients. J Clin Endocrinol Metab 1999;784:2518–2522.

    Google Scholar 

  13. Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999;22:354–359.

    CAS  PubMed  Google Scholar 

  14. Bronstein MD, Musolino NR, Benabou S, Marino R Jr. Cerebrospinal fluid rhinorrhea occurring in long-term bromocriptine treatment for macroprolactinomas. Surg Neurol 1989;32:346–349.

    CAS  PubMed  Google Scholar 

  15. Jalali R, Brada M, Perks JR, Warrington AP, Traish D, Burchell L, McNair H, Thomas DG, Robinson S, Johnston DG. Stereotactic conformal radiotherapy for pituitary adenomas: technique and preliminary experience. Clin Endocrinol (Oxf) 2000;52:695–702.

    Article  CAS  Google Scholar 

  16. Inoue HK, Kohga H, Hirato M, Sasaki T, Shihara J, Shibazaki T, Ohye C, Andou Y. Pituitary adenomas treated by microsurgery with or without Gamma Knife surgery: Experience in 122 cases. Stereotact Funct Neurosurg 1999;72:125–131.

    Article  PubMed  Google Scholar 

  17. Morange-Ramos I, Regis J, Dufor H, Andrieu JM, Grisoli F, Jaquet P, Peragaut JC. Short-term endocrinological results after gamma knife surgery of pituitary adenomas. Stereotact Funct Neurosurg 1998;70:127–138.

    PubMed  Google Scholar 

  18. Elster AD, Sanders TG, Vines FS, Chen MY. Size and shape of the pituitary gland during pregnancy and post partum: Measurement with M R imaging. Radiology 1991;181:531–500.

    CAS  PubMed  Google Scholar 

  19. Dinc H, Esen F, Demirci A, Sari A, Resit Gumele H. Pituitary dimensions and volume measurements in pregnancy and post partum M R assessment. Acta Radiol 1998;39:64–69.

    CAS  PubMed  Google Scholar 

  20. Gonzalez JG, Elizondo G, Saldriar D, Nanez H, Todd LE, Vielarreal JZ. Pituitary gland growth during normal pregnancy: An in vivo study using magnetic resonance imaging. Am J Med 1988;85:217–220.

    Article  CAS  PubMed  Google Scholar 

  21. Scheithauer BW, Sano T, Kovacs KT, Young WFJr, Ryan N, Randall RV. The pituitary gland in pregnancy: A clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin Proc 1990;65:461–474.

    CAS  PubMed  Google Scholar 

  22. Rigg LA, Lein A, Yen SSC. Pattern of increase in circulating prolactin levels during human gestation. Am J Obstet Gynecol 1977;129:454–456.

    CAS  PubMed  Google Scholar 

  23. Ferriani RA, Silva de Sá MF, Lima Filho EC. A comparative study of longitudinal and cross-sectional changes in plasma levels of prolactin and estriol during normal pregnancy. Brazilian J Med Biol Res 1986;19:183–188.

    CAS  Google Scholar 

  24. Zegher F, Spitz B, Van der Berghe G, Lemmens D, Vanweser K, Keppens K, Bowers CY. Postpartum hyperprolactinemia and hyporesponsiveness of growth hormone to GH-releasing peptide. J Clin Endocrinol Metab 1998;83:103–106.

    PubMed  Google Scholar 

  25. Delvoye P, Delogne-Desnoeck J, Robyn C. Hyperprolactinaemia during prolonged lactation: Evidence for anovulatory cycles and inadequate corpus luteum. Clin Endocrinol 1980;13:243–247.

    CAS  Google Scholar 

  26. Gemzell C, Wang CF. Outcome of pregnancy in women with pituitary adenoma. Fertil Steril 1979;31:363–372.

    CAS  PubMed  Google Scholar 

  27. Krupp P, Monka C. Bromocriptine in Pregnancy: Safety Aspects. Klin Wochenschr 1987;65:823–827.

    Article  CAS  PubMed  Google Scholar 

  28. Weil C. The safety of bromocriptine in long-term use: A review of the literature. Curr Res Opin 1986;10:25–51.

    CAS  Google Scholar 

  29. Krupp P, Monka C, Richter K. The safety aspects of infertility treatments. Program of the Second Word Congress of Gynecology and Obstetrics, Rio de Janeiro, Brazil, 1988.

  30. Chiodini I, Liuzzi A. PRL-secreting adenomas in pregnancy. J Endocrinol Invest 2003;96–99.

  31. Musolino NRC, Bronstein MD. Prolactinomas and Pregnancy. In: Bronstein MD (ed.), Pituitary Tumors in Pregnancy. Boston, Kluwer Academic Publishers, 2001, pp. 91–108.

    Google Scholar 

  32. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med 1985;312:1364–1370.

    Article  CAS  PubMed  Google Scholar 

  33. Ferrer-Barriendos J, Millet A, Lucas-Pinilla E. Necrosis de un prolactinoma durante el embarazo. Rev Esp Obst Gin 1981;40:578–585.

    Google Scholar 

  34. Holmgren U, Bergstrand G, Hagenfeldt K, Werner S. Women with prolactinoma—effect of pregnancy and lactation on serum prolactin and on tumour growth. Acta Endocrinol (Copenh) 1986;111:452–459.

    CAS  Google Scholar 

  35. Shewchuk AB, Adamson GD, Lessard P, Ejrin C. The effect of pregnancy on suspected pituitary adenomas after conservative management of ovulation defects associated with galactorrhea. Am J Obstet Gynecol 1980;136:659–666.

    CAS  PubMed  Google Scholar 

  36. Child DF, Gordon H, Mashiter K, Jopkin GF. Pregnancy, prolactin, and pituitary tumours. Br Med J 1975;4:87–89.

    CAS  PubMed  Google Scholar 

  37. van Roon E, van der Vijver JCM, Gerretsen G, Hekster REM, Wattendorff RA. Rapid regression of a suprasellar extending prolactinoma after bromocriptine treatment during pregnancy. Fertil and Steril 1981;36:173–177.

    CAS  Google Scholar 

  38. Maeda T, Ushiroyama T, Okuda K, Fujimoto A, Ueki M, Sugimoto O. Effective bromocriptine treatment of a pituitary macroadenoma during pregnancy. Obstet Gynecol 1983;61:117–120.

    CAS  PubMed  Google Scholar 

  39. Brodsky JB, Cohen EN, Brown BWJr, Wu ML, Whitcher C. Surgery during pregnancy and fetal outcome. Am J Obstet Gynecol 1980;138:1165–1167.

    CAS  PubMed  Google Scholar 

  40. Bergh T, Nillius SJ, Wide L. Clinical course and outcome of pregnancies in amenorrhoeic women with hyperprolactinaemia and pituitary tumours. Br Med J 1978;1:875–880.

    Article  CAS  PubMed  Google Scholar 

  41. Tan SL, Jacobs HS. Rapid regression through bromocriptine therapy of a suprasellar extending prolactinoma during pregnancy. Int J Gynaecol Obstet 1986;24:209–215.

    Article  CAS  PubMed  Google Scholar 

  42. Canales ES, Garcia IC, Ruiz JE, Zarate A. X Bromocriptine as prophylactic therapy in prolactinoma during pregnancy. Fertil and Steril 1986;36:524–526.

    Google Scholar 

  43. Konopka P, Raymond JP, Merceron RE, Seneze J. Continuous administration of bromocriptine in the prevention of neurological complications in pregnant women with prolactinomas. Am J Obstet Gynecol 1983;146:935–938.

    CAS  PubMed  Google Scholar 

  44. Molitch ME. Pituitary diseases in pregnancy. Semin Perinatol 1998;22:457–470.

    CAS  PubMed  Google Scholar 

  45. Morange I, Barlier A, Pellegrini I, Brue T, Enjalbert A, Jaquet P. Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy. Eur J Endocrinol 1996;135:413–420.

    Article  CAS  PubMed  Google Scholar 

  46. Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol 1996;10:333–337.

    CAS  PubMed  Google Scholar 

  47. Cannavo S, Curto L, Squadrito S, et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 1999;22:354–359.

    CAS  PubMed  Google Scholar 

  48. Verhelst J, Abs R, Maiter D, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 1999;84:2518–2522.

    CAS  PubMed  Google Scholar 

  49. Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, et al. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol 2002;16:791–793.

    Article  CAS  PubMed  Google Scholar 

  50. Liu C, Tyrrell JB. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy. Pituitary 2001;4:179–185.

    Article  CAS  PubMed  Google Scholar 

  51. Bronstein MD, Salgado LR, Musolino NR. Medical management of pituitary adenomas: The special case of the pregnant woman. Pituitary 2002;5:99–107.

    Article  CAS  PubMed  Google Scholar 

  52. Zárate A, Canales ES, Alger M, Forsbach G. The effect of pregnancy and lactation on pituitary prolactin-secreting tumours. Acta Endocrinol (Copenh) 1979;92:407–412.

    Google Scholar 

  53. Bronstein MD, Musolino NR, Cardim CS, Marino RJr. Outcome of 52 pregnancies in hyperprolactinemic women. Rev Bras Ginecol Obstet 1988;10:175–178.

    Google Scholar 

  54. Bronstein MD, Musolino NR, Cardim C, Monteiro M, Marino RJr. Repeatable depot-bromocriptine treatment for prolactinomas. In: Meireles RMR, Machado A, Póvoa LC (eds.), Clinical Endocrinology: Proceedings of the 18th Brazilian Congress of Endocrinology and Metabolism, Rio de Janeiro, 1988;Junho pp. 12–17, Amsterdam-New York-Oxford: Excepta Medica. 1988, pp. 45–48.

  55. Crosignani PG, Mattei AM, Severini V, Cavioni V, Maggioni P, Testa G. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur J Obstet Gynecol Reprod Biol 1992;44:175–180.

    Article  CAS  PubMed  Google Scholar 

  56. Rjosk HK, Fahlbusch R, von Werder K. Influence of pregnancies on prolactinomas. Acta Endocrinol (Copenh) 1982;100:337–346.

    CAS  Google Scholar 

  57. Badawy SZ, Marziale JC, Rosenbaum AE, Chang JK, Joy SE. The long-term effects of pregnancy and bromocriptine treatment on prolactinomas—the value of radiologic studies. Early Pregnancy 1997;3:306–311.

    CAS  PubMed  Google Scholar 

  58. Ahmed M, al-Dossary E, Woodhouse NJ. Macroprolactinomas with suprasellar extension: Effect of bromocriptine withdrawal during one or more pregnancies. Fertil Steril 1992;58:492–497.

    CAS  PubMed  Google Scholar 

  59. Peillon F, Racadot J, Moussy D, Vila-Porcile E, Olivier L, Racadot O. Prolactin-secreting adenomas. A correlative study of morphological and clinical data. In: Fahlbusch R., Von Werder K. (eds.), Treatament of pituitary adenomas. Stuttgart: Thiemi, 1978, pp. 114.

    Google Scholar 

  60. Freeman R, Wezenter B, Silvestein M, Kuo D, Weiss KL, Kantrowitz AB, Schubart UK. Pregnancy-associated subacute hemorrhage into a prolactinoma resulting in diabetes insipidus. Fertil Steril 1992;58:427–429.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, University of S. Paulo Medical School, Brazil

    Marcello Delano Bronstein

  2. Neuroendocrine Unit, Division of Endocrinology and Metabolism, Hospital das Clínicas, University of S. Paulo Medical School, Av 9 de Julho 3858, 01406-100, S. Paulo, SP, Brazil

    Marcello Delano Bronstein

Authors
  1. Marcello Delano Bronstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcello Delano Bronstein.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bronstein, M.D. Prolactinomas and Pregnancy. Pituitary 8, 31–38 (2005). https://doi.org/10.1007/s11102-005-5083-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-005-5083-4

Key Words

Search

Navigation